**NEPHROS INC** Form 3 October 01, 2007

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

C/O WEXFORD CAPITAL

LLC, 411 WEST PUTNAM

Person \*

À Lambda Investors LLC

(Last)

**AVENUE** 

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Statement

(Month/Day/Year)

09/19/2007

4. Relationship of Reporting

Person(s) to Issuer

NEPHROS INC [NEP]

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

(Street)

\_X\_ 10% Owner Director Officer Other (give title below) (specify below)

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

GREENWICH, CTÂ 06830

(City) (State)

1. Title of Security

(Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Form: Direct (D) or Indirect (I)

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. 5. Conversion Ownership

Security

6. Nature of Indirect Beneficial Ownership

(Instr. 4)

**Expiration Title** Exercisable Date

Amount or Number of

Form of or Exercise Derivative Price of Derivative Security:

Direct (D)

(Instr. 5)

### Edgar Filing: NEPHROS INC - Form 3

Shares or Indirect (I) (Instr. 5) Common Stock and Series A 10% Secured Warrants 21,246,459  $\hat{A}^{(1)}$  $\hat{A}^{(2)}$ \$ 0.706 (4) Â Convertible Note due D 2008 Purchase Common Stock

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

Lambda Investors LLC

C/O WEXFORD CAPITAL LLC
411 WEST PUTNAM AVENUE

GREENWICH, CTÂ 06830

## **Signatures**

Arthur H. Amron, Vice President and Assistant Secretary

10/01/2007

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Note will automatically convert on the twenty-first (21st) day after the issuer sends or gives its stockholders a definitive Schedule
- (1) 14C information statement relating to certain actions taken by stockholders of the issuer by written consent (the ?Automatic Conversion Date?).
- (2) The maturity date of the Note is September 19, 2008.
  - The number reported includes 14,164,306 shares of Common Stock and warrants to purchase an additional 7,082,153 shares of Common Stock. The number of shares and warrants reported is based on the original principal amount of the Note (\$10,000,000). The Note accrues
- (3) interest at a rate of 10% per annum, and the accrued interest will automatically be converted into shares of Common Stock on the Automatic Conversion Date at the same conversion rate as the rate that applies to the original principal amount. The number of warrants issued upon conversion of the Note will increase by 50% of the number of shares of Common Stock issued with respect to the accrued interest.
- (4) The amount reported represents the conversion price used to determine the number of shares of Common Stock issuable upon the conversion of the Note. The exercise price of the warrants that will be issued upon the conversion of the Note is \$0.90 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2